48,000 Shares in Inovio Pharmaceuticals Inc (INO) Purchased by Wellington Shields & Co. LLC

Wellington Shields & Co. LLC purchased a new position in shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 48,000 shares of the biopharmaceutical company’s stock, valued at approximately $267,000.

Other institutional investors also recently made changes to their positions in the company. Guggenheim Capital LLC acquired a new stake in shares of Inovio Pharmaceuticals during the 1st quarter worth approximately $2,375,000. BlackRock Inc. raised its position in shares of Inovio Pharmaceuticals by 5.5% during the 2nd quarter. BlackRock Inc. now owns 6,845,338 shares of the biopharmaceutical company’s stock worth $26,834,000 after purchasing an additional 356,105 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Inovio Pharmaceuticals by 50.2% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 101,225 shares of the biopharmaceutical company’s stock worth $397,000 after purchasing an additional 33,825 shares during the period. UBS Group AG raised its position in shares of Inovio Pharmaceuticals by 156.7% during the 1st quarter. UBS Group AG now owns 442,893 shares of the biopharmaceutical company’s stock worth $2,086,000 after purchasing an additional 270,373 shares during the period. Finally, ARK Investment Management LLC raised its position in shares of Inovio Pharmaceuticals by 79.8% during the 2nd quarter. ARK Investment Management LLC now owns 1,194,657 shares of the biopharmaceutical company’s stock worth $4,683,000 after purchasing an additional 530,247 shares during the period. Institutional investors and hedge funds own 31.71% of the company’s stock.

In related news, CEO Jong Joseph Kim sold 49,060 shares of the firm’s stock in a transaction that occurred on Wednesday, September 12th. The stock was sold at an average price of $5.37, for a total value of $263,452.20. Following the sale, the chief executive officer now directly owns 2,357,554 shares in the company, valued at approximately $12,660,064.98. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 9.40% of the stock is owned by company insiders.

Several analysts recently commented on INO shares. Stifel Nicolaus started coverage on Inovio Pharmaceuticals in a research report on Tuesday, October 2nd. They issued a “buy” rating and a $8.00 target price on the stock. HC Wainwright set a $13.00 target price on Inovio Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, September 18th. BidaskClub cut Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, October 26th. Finally, ValuEngine cut Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, August 30th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. Inovio Pharmaceuticals has an average rating of “Hold” and a consensus target price of $10.75.

INO traded up $0.13 during trading hours on Friday, hitting $5.32. The company’s stock had a trading volume of 20,917 shares, compared to its average volume of 901,890. Inovio Pharmaceuticals Inc has a fifty-two week low of $3.64 and a fifty-two week high of $6.30. The stock has a market cap of $460.23 million, a P/E ratio of -4.67 and a beta of 1.88.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.05. Inovio Pharmaceuticals had a negative return on equity of 71.53% and a negative net margin of 252.95%. The firm had revenue of $2.00 million for the quarter, compared to analysts’ expectations of $2.20 million. During the same period last year, the firm earned ($0.39) EPS. As a group, equities analysts predict that Inovio Pharmaceuticals Inc will post -1.06 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was originally posted by WKRB News and is the sole property of of WKRB News. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.wkrb13.com/2018/11/10/48000-shares-in-inovio-pharmaceuticals-inc-ino-purchased-by-wellington-shields-co-llc.html.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

Further Reading: How to calculate the intrinsic value of a stock

Want to see what other hedge funds are holding INO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inovio Pharmaceuticals Inc (NASDAQ:INO).

Institutional Ownership by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply